US clinical-stage biopharma company Viking Therapeutics (Nasdaq: VKTX) saw its shares close up nearly 70% at $15.44 yesterday, after it released encouraging early-stage data on its obesity candidate VK2735.
The compound is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders. Based on these Phase I results, the company plans to initiate a Phase II study of VK2735 in patients with obesity in mid-2023.
Depending on the success of the drug in upcoming studies, Viking would compete in a potential $50 billion market for obesity treatment, with industry heavyweights such as Eli Lilly (NYSE: LLY) and Novo Nordisk (NOV: N).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze